Evidence map›Paper›PMID 42012295›Full record

ArticleInfection and immunity2026

Construction and characterization of novel

Omar Garnica, Raja Veerapandian, Kishore Das, Abhishek Mishra, Varsha Rawat, Areanna Carmona, Vivek Chauhan, Rakesh Kumar, Jessica Chacon, Arshad Khan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Omar GarnicaCenter of Emphasis in Infectious Diseases, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Raja VeerapandianCenter of Emphasis in Infectious Diseases, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Kishore DasCenter of Emphasis in Infectious Diseases, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Abhishek MishraDepartment of Pathology and Genomic Medicine, Houston Methodist Research Institute & Weill Cornell Medical College, Houston, Texas, USA.ORCID 0000-0003-2077-0937
Varsha RawatDepartment of Pathology and Genomic Medicine, Houston Methodist Research Institute & Weill Cornell Medical College, Houston, Texas, USA.
Areanna CarmonaCenter of Emphasis in Infectious Diseases, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Vivek ChauhanCenter of Emphasis in Infectious Diseases, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Rakesh KumarCenter of Emphasis in Infectious Diseases, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Jessica ChaconDepartment of Medical Education, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Arshad KhanDepartment of Pathology and Genomic Medicine, Houston Methodist Research Institute & Weill Cornell Medical College, Houston, Texas, USA.
Enrique I RamosDepartment of Biological Sciences, University of Texas El Paso, El Paso, Texas, USA.
Shrikanth S GadadCenter of Emphasis in Cancer, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Chinnaswamy JagannathDepartment of Pathology and Genomic Medicine, Houston Methodist Research Institute & Weill Cornell Medical College, Houston, Texas, USA.ORCID 0000-0002-3014-2857
Subramanian DhandayuthapaniCenter of Emphasis in Infectious Diseases, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.ORCID 0009-0001-4390-3811

Funding

Novel Stem Cell Immunotherapy for MDR-TuberculosisR01AI161015 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ENDSLEY, JANICE J, JAGANNATH, CHINNASWAMY · 2021 to 2025
$4.8M
Sirtuin -Dependent Regulation of Tuberculosis and HIV Interactions in MacrophagesR01AI184551 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Janice J Endsley, Chinnaswamy Jagannath · 2024 to 2026
$3.8M
Regulation of innate immunity by self-adjuvated MRNA vaccinesR01AI184394 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI JAGANNATH, CHINNASWAMY · 2025 to 2025
$2.7M
A Novel Hyper-Immunogenic Low Virulent BCG vaccine against TuberculosisR01AI175837 · NIAID · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI SUBRAMANIAN DHANDAYUTHAPANI · 2023 to 2026
$2.0M
Molecular basis of BCG vaccine sub-strain heterogeneityR01AI187440 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Jeffrey D. Cirillo, Chinnaswamy Jagannath · 2025 to 2026
$1.5M
A novel quadruple knockout MTb vaccine against tuberculosis (Supplement Resubmission)R15AI156647 · NIAID · TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER AT EL PASO · PI DHANDAYUTHAPANI, SUBRAMANIAN · 2021 to 2023
$626k
Analysis of Divergent Transcripts in Estrogen-Dependent SignalingR16GM149497 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI Shrikanth Gadad · 2023 to 2026
$620k
American Cancer Society RSG-22-170-01-RMCNational Institute of Allergy and Infectious Diseases 1R15AI156647; 1RO1AI175837National Institute of Allergy and Infectious Diseases R01AI161015, R01AI184551, R01AI184394, R01AI187440NIAID NIH HHS R01 AI161015NIAID NIH HHS R01 AI175837NIAID NIH HHS R01 AI184394NIAID NIH HHS R01 AI184551NIAID NIH HHS R01 AI187440NIAID NIH HHS R15 AI156647NIGMS NIH HHS R16 GM149497NIGMS NIH HHS R16GM149497
6 · The paper itself

Abstract

Tuberculosis (TB) is a deadly disease that claims the lives of over a million people each year worldwide. The Bacille Calmette-Guérin vaccine has long been used to protect against TB, but it produces variable effects across different populations and fails to protect against adult pulmonary TB. Therefore, there is an urgent need for alternative vaccines that can offer better protection. We have developed a strategy for the rational deletion of virulence-related genes in

Indexed as

Mycobacterium tuberculosisTuberculosisTuberculosis VaccinesAnimalsBacterial ProteinsDisease Models, AnimalFemaleGene DeletionGene Knockout TechniquesMiceVaccines, AttenuatedBacterial ProteinsTuberculosis VaccinesVaccines, Attenuatedattenuated live vaccinesgene deletionimmunogenicityMycobacterium tuberculosisprotectionsafetySCID mousetuberculosis

Identifiers

PMID42012295
PMCPMC13163195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.